DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Shirasugi Y, Ando K, Miyazaki K. , et al.
An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
Int J Hematol 2012;
95 (06) 652-659
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.